Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7993)
All Articles published online
|
Jan 7, 2008 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Höpfner M, Schuppan D, Scherübl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008; 14(1): 1-14 [PMID: 18176955 DOI: 10.3748/wjg.14.1] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i1/1.htm |
| Number | Citing Articles |
| 1 |
Takahito Yagi. . Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 2008; 120(1): 63 doi: 10.4044/joma.120.63
|
| 2 |
Masatoshi Kudo. Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. International Journal of Clinical Oncology 2010; 15(3): 242 doi: 10.1007/s10147-010-0089-y
|
| 3 |
Meng He, Qiuyu Liao, Dong Liu, Xufang Dai, Meihua Shan, Mingzhen Yang, Yang Zhang, Liuyue Zhai, Lingxi Chen, Li Xiang, Mei He, Shuhui Li, An Chen, Liangbo Sun, Jiqin Lian. Dihydroergotamine mesylate enhances the anti-tumor effect of sorafenib in liver cancer cells. Biochemical Pharmacology 2023; 211: 115538 doi: 10.1016/j.bcp.2023.115538
|
| 4 |
Christèle Desbois-Mouthon, Aurore Baron, Marie-José Blivet-Van Eggelpoël, Laetitia Fartoux, Corinne Venot, Friedhelm Bladt, Chantal Housset, Olivier Rosmorduc. Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma. Clinical Cancer Research 2009; 15(17): 5445 doi: 10.1158/1078-0432.CCR-08-2980
|
| 5 |
C. Berasain, J. Castillo, M.J. Perugorria, M.U. Latasa, J. Prieto, M.A. Avila. Inflammation and Liver Cancer. Annals of the New York Academy of Sciences 2009; 1155(1): 206 doi: 10.1111/j.1749-6632.2009.03704.x
|
| 6 |
B Nitzsche, C Gloesenkamp, M Schrader, M Ocker, R Preissner, M Lein, A Zakrzewicz, B Hoffmann, M Höpfner. Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours. British Journal of Cancer 2010; 103(1): 18 doi: 10.1038/sj.bjc.6605725
|
| 7 |
Rebecca Allen, Daneng Li. Oncology in the Precision Medicine Era. 2020; : 259 doi: 10.1007/978-3-030-31471-2_16
|
| 8 |
Mai Sayed Fouad, Mosad A. Ghareeb, Ahmed A. Hamed, Esraa A. Aidy, Jioji Tabudravu, Ahmed M. Sayed, Mohamed A. Tammam, Mai Ali Mwaheb. Exploring the antioxidant, anticancer and antimicrobial potential of Amaranthus viridis L. collected from Fayoum depression: Phytochemical, and biological aspects. South African Journal of Botany 2024; 166: 297 doi: 10.1016/j.sajb.2024.01.047
|
| 9 |
Chareeporn Akekawatchai, Marina Kochetkova, Jane Holland, Shaun R McColl. Chemokine Receptors in Cancer. 2009; : 1 doi: 10.1007/978-1-60327-267-4_1
|
| 10 |
Mona A. Omar, Mohamed M. Omran, Khaled Farid, Ashraf A. Tabll, Yasser E. Shahein, Tarek M. Emran, Ana Petrovic, Nikola R. Lucic, Robert Smolic, Tanja Kovac, Martina Smolic. Biomarkers for Hepatocellular Carcinoma: From Origin to Clinical Diagnosis. Biomedicines 2023; 11(7): 1852 doi: 10.3390/biomedicines11071852
|
| 11 |
Shinji Tanaka, Shigeki Arii. Molecularly targeted therapy for hepatocellular carcinoma. Kanzo 2008; 49(4): 133 doi: 10.2957/kanzo.49.133
|
| 12 |
Li Chen, Yan Shi, Cheng-ying Jiang, Li-xin Wei, Ya-li Lv, Yu-lan Wang, Guang-hai Dai. Coexpression of PDGFR-Alpha, PDGFR-Beta and VEGF as a Prognostic Factor in Patients with Hepatocellular Carcinoma. The International Journal of Biological Markers 2011; 26(2): 108 doi: 10.5301/JBM.2011.8322
|
| 13 |
Silvia Ribback, Verena Sailer, Enrico Böhning, Julia Günther, Jaqueline Merz, Frauke Steinmüller, Kirsten Utpatel, Antonio Cigliano, Kristin Peters, Maria Pilo, Matthias Evert, Diego Calvisi, Frank Dombrowski. The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models. International Journal of Molecular Sciences 2016; 17(10): 1618 doi: 10.3390/ijms17101618
|
| 14 |
María J. Cuevas, Juliana Tieppo, Norma Possa Marroni, María J. Tuñón, Javier González-Gallego. Suppression of Amphiregulin/Epidermal Growth Factor Receptor Signals Contributes to the Protective Effects of Quercetin in Cirrhotic Rats ,. The Journal of Nutrition 2011; 141(7): 1299 doi: 10.3945/jn.111.140954
|
| 15 |
Thorsten Maass, Florian R. Thieringer, Amrit Mann, Thomas Longerich, Peter Schirmacher, Dennis Strand, Torsten Hansen, Peter R. Galle, Andreas Teufel, Stephan Kanzler. Liver specific overexpression of platelet‐derived growth factor‐B accelerates liver cancer development in chemically induced liver carcinogenesis. International Journal of Cancer 2011; 128(6): 1259 doi: 10.1002/ijc.25469
|
| 16 |
Sania Safdar Butt, Khushbukhat Khan, Yasmin Badshah, Mehak Rafiq, Maria Shabbir. Evaluation of pro-apoptotic potential of taxifolin against liver cancer. PeerJ 2021; 9: e11276 doi: 10.7717/peerj.11276
|
| 17 |
Yue Ma, Ying-Chun Xu, Lei Tang, Zan Zhang, Jian Wang, Hong-Xia Wang. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Experimental Hematology & Oncology 2012; 1(1) doi: 10.1186/2162-3619-1-11
|
| 18 |
D. Koeberle, P. Samaras. Recent advances and future challenges in the treatment of hepatocellular and biliary tract carcinomas. memo - Magazine of European Medical Oncology 2011; 4(2): 94 doi: 10.1007/s12254-011-0260-9
|
| 19 |
Carmen Berasain, Maria J. Perugorria, Maria Ujue Latasa, Josefa Castillo, Saioa Goñi, Mónica Santamaría, Jesús Prieto, Matías A. Avila. The Epidermal Growth Factor Receptor: A Link Between Inflammation and Liver Cancer. Experimental Biology and Medicine 2009; 234(7): 713 doi: 10.3181/0901-MR-12
|
| 20 |
Churen Zhou, Duo Zhu, Sibin Zhou, Haofan Wang, Mingsheng Huang. Screening differential circular RNA expression profiles and the potential role of hsa_circ_0085465 in liver cancer. Journal of Cancer Research and Therapeutics 2023; 19(3): 548 doi: 10.4103/jcrt.jcrt_1868_20
|
| 21 |
Amanda Psyrri, Nikolaos Arkadopoulos, Maria Vassilakopoulou, Vassilios Smyrniotis, George Dimitriadis. Pathways and targets in hepatocellular carcinoma. Expert Review of Anticancer Therapy 2012; 12(10): 1347 doi: 10.1586/era.12.113
|
| 22 |
Haiyu Li, Zhenggang Ren, Xiaonan Kang, Lan Zhang, Xuefei Li, Yan Wang, Tongchun Xue, Yuefang Shen, Yinkun Liu. Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells. BMC Cancer 2009; 9(1) doi: 10.1186/1471-2407-9-366
|
| 23 |
Vladimir Beljanski, Clayton S. Lewis, Charles D. Smith. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biology & Therapy 2011; 11(5): 524 doi: 10.4161/cbt.11.5.14677
|
| 24 |
Jürgen S. Scheele, Jan Harder, Zoran Stankovic, Daniel Räpple, Annette Dorn, Hans C. Spangenberg, Hubert E. Blum. Clinical response to Auron Misheil Therapy in a man with advanced multifocal hepatocellular carcinoma: A case report. Journal of Medical Case Reports 2011; 5(1) doi: 10.1186/1752-1947-5-478
|
| 25 |
Ji‐Hua Shi, Shu‐Zheng Liu, Lene Wierød, Hanne Scholz, Jarl Andreas Anmarkrud, Henrik S. Huitfeldt, Shui‐Jun Zhang, Pål‐Dag Line. RAF‐targeted therapy for hepatocellular carcinoma in the regenerating liver. Journal of Surgical Oncology 2013; 107(4): 393 doi: 10.1002/jso.23224
|
| 26 |
Maureen P. Kohi, Nicholas Fidelman, David M. Naeger, Jeanne M. LaBerge, Roy L. Gordon, Robert K. Kerlan. Hepatotoxicity after Transarterial Chemoembolization and Transjugular Intrahepatic Portosystemic Shunt: Do Two Rights Make a Wrong?. Journal of Vascular and Interventional Radiology 2013; 24(1): 68 doi: 10.1016/j.jvir.2012.08.032
|
| 27 |
Brian I. Carr, Susan Kralian. Hepatocellular Carcinoma. 2009; : 589 doi: 10.1007/978-1-60327-376-3_22
|
| 28 |
Xiaofeng Li, Dong Dai, Xiuyu Song, Jianjing Liu, Lei Zhu, Wengui Xu. A meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology 2014; 38(5): 583 doi: 10.1016/j.clinre.2014.04.010
|
| 29 |
Quirino Lai, Alessandro Vitale, Tommaso Manzia, Francesco Foschi, Giovanni Levi Sandri, Martina Gambato, Fabio Melandro, Francesco Russo, Luca Miele, Luca Viganò, Patrizia Burra, Edoardo Giannini. Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics. Cancers 2019; 11(10): 1568 doi: 10.3390/cancers11101568
|
| 30 |
Chiao-Fang Teng, Han-Chieh Wu, Woei-Cherng Shyu, Long-Bin Jeng, Ih-Jen Su. Pre-S2 Mutant-Induced Mammalian Target of Rapamycin Signal Pathways as Potential Therapeutic Targets for Hepatitis B Virus-Associated Hepatocellular Carcinoma. Cell Transplantation 2017; 26(3): 429 doi: 10.3727/096368916X694382
|
| 31 |
Thi Bich Uyen Le, Thanh Chung Vu, Rebecca Zhi Wen Ho, Aldo Prawira, Lingzhi Wang, Boon Cher Goh, Hung Huynh. Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma. International Journal of Molecular Sciences 2020; 21(24): 9405 doi: 10.3390/ijms21249405
|
| 32 |
Xuan Wang, Jieyu Ding, Yuanyuan Feng, Lingling Weng, Guangqiang Zhao, Jianfeng Xiang, Minguang Zhang, Dongwei Xing. Targeting of growth factors in the treatment of hepatocellular carcinoma: The potentials of polysaccharides. Oncology Letters 2017; 13(3): 1509 doi: 10.3892/ol.2017.5602
|
| 33 |
K Ashokachakkaravarthy, Biju Pottakkat. Sorafenib resistance and autophagy in hepatocellular carcinoma: A concealed threat. Journal of Cancer Research and Practice 2019; 6(3): 107 doi: 10.4103/JCRP.JCRP_6_19
|
| 34 |
Yunsheng Zhao, Qin Gao, Liu Pei, Chunhua Wang, Liang Jin, Fei Liao. Current Status and Future Prospects of Biomarkers in the Diagnosis of Hepatocellular Carcinoma. The International Journal of Biological Markers 2017; 32(4): 361 doi: 10.5301/ijbm.5000299
|
| 35 |
Andrea N. Chisari, Patricia Sancho, Laia Caja, Esther Bertran, Isabel Fabregat. Lack of amino acids in mouse hepatocytes in culture induces the selection of preneoplastic cells. Cellular Signalling 2012; 24(1): 325 doi: 10.1016/j.cellsig.2011.09.018
|
| 36 |
Ziqiang Li, Mei Tang, Bo Ling, Shiying Liu, Yu Zheng, Chunlai Nie, Zhu Yuan, Liangxue Zhou, Gang Guo, Aiping Tong, Yuquan Wei. Increased expression of S100A6 promotes cell proliferation and migration in human hepatocellular carcinoma. Journal of Molecular Medicine 2014; 92(3): 291 doi: 10.1007/s00109-013-1104-3
|
| 37 |
Dieter Koeberle, Michael Montemurro, Panagiotis Samaras, Pietro Majno, Mathew Simcock, Andreas Limacher, Stefanie Lerch, Katalin Kovàcs, Roman Inauen, Vivianne Hess, Piercarlo Saletti, Markus Borner, Arnaud Roth, György Bodoky. Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06). The Oncologist 2010; 15(3): 285 doi: 10.1634/theoncologist.2009-0316
|
| 38 |
Takao Watanabe, Hiroko Ninomiya, Takashi Saitou, Sota Takanezawa, Shin Yamamoto, Yusuke Imai, Osamu Yoshida, Ryosuke Kawakami, Masashi Hirooka, Masanori Abe, Takeshi Imamura, Yoichi Hiasa. Therapeutic effects of the PKR inhibitor C16 suppressing tumor proliferation and angiogenesis in hepatocellular carcinoma in vitro and in vivo. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-61579-x
|
| 39 |
Mónica Enguita-Germán, Puri Fortes. Targeting the insulin-like growth factor pathway in hepatocellular carcinoma. World Journal of Hepatology 2014; 6(10): 716-737 doi: 10.4254/wjh.v6.i10.716
|
| 40 |
Melanie B. Thomas, Elizabeth Garrett-Mayer, Munazza Anis, Kate Anderton, Tricia Bentz, Andie Edwards, Alan Brisendine, Geoffrey Weiss, Abby B. Siegel, Johanna Bendell, Ari Baron, Vinay Duddalwar, Anthony El-Khoueiry. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. Oncology 2018; 94(6): 329 doi: 10.1159/000485384
|
| 41 |
Jian Zhu, Yanping Wang, Yunhui Yu, Zheng Wang, Tingting Zhu, Xiukun Xu, Haiyan Liu, David Hawke, Dapeng Zhou, Yunsen Li. Aberrant fucosylation of glycosphingolipids in human hepatocellular carcinoma tissues. Liver International 2014; 34(1): 147 doi: 10.1111/liv.12265
|
| 42 |
Marcus Alexander Wörns, Peter Robert Galle. Novel inhibitors in development for hepatocellular carcinoma. Expert Opinion on Investigational Drugs 2010; 19(5): 615 doi: 10.1517/13543781003767418
|
| 43 |
Iulia Minciuna, Laurens A. van Kleef, Horia Stefanescu, Bogdan Procopet. Is Fasting Good When One Is at Risk of Liver Cancer?. Cancers 2022; 14(20): 5084 doi: 10.3390/cancers14205084
|
| 44 |
Johannes Lammer, Katarina Malagari, Thomas Vogl, Frank Pilleul, Alban Denys, Anthony Watkinson, Michael Pitton, Geraldine Sergent, Thomas Pfammatter, Sylvain Terraz, Yves Benhamou, Yves Avajon, Thomas Gruenberger, Maria Pomoni, Herbert Langenberger, Marcus Schuchmann, Jerome Dumortier, Christian Mueller, Patrick Chevallier, Riccardo Lencioni. Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study. CardioVascular and Interventional Radiology 2010; 33(1): 41 doi: 10.1007/s00270-009-9711-7
|
| 45 |
Munawar Abbas, Farhan Saeed, Faqir Muhammad Anjum, Muhammad Afzaal, Tabussam Tufail, Muhammad Shakeel Bashir, Adnan Ishtiaq, Shahzad Hussain, Hafiz Ansar Rasul Suleria. Natural polyphenols: An overview. International Journal of Food Properties 2017; 20(8): 1689 doi: 10.1080/10942912.2016.1220393
|
| 46 |
A C Hoover, G L Strand, P N Nowicki, M E Anderson, P D Vermeer, A J Klingelhutz, A D Bossler, J V Pottala, WJAJ Hendriks, J H Lee. Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway. Oncogene 2009; 28(45): 3960 doi: 10.1038/onc.2009.251
|
| 47 |
Andrew Scanga, Kris Kowdley, Kris Kowdley, Geoffrey McCaughan, Christian Trautwein. Sorafenib. Hepatology 2009; 49(1): 332 doi: 10.1002/hep.22756
|
| 48 |
Meng Zhao, Hong-wei He, Huan-xing Sun, Kai-huan Ren, Rong-guang Shao. Dual knockdown of N-ras and epiregulin synergistically suppressed the growth of human hepatoma cells. Biochemical and Biophysical Research Communications 2009; 387(2): 239 doi: 10.1016/j.bbrc.2009.06.128
|
| 49 |
Ronald Koschny, Carsten Grüllich, Tom Michael Ganten. Standards und neue Aspekte der Diagnostik und Therapie des hepatozellulären Karzinoms. Onkopipeline 2008; 1(3): 109 doi: 10.1007/s15035-008-0136-6
|
| 50 |
Hung Huynh. AZD6244 (ARRY‐142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma. Cancer 2010; 116(5): 1315 doi: 10.1002/cncr.24863
|
| 51 |
Eyal Mishani, Aviv Hagooly. Strategies for Molecular Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase in Cancer. Journal of Nuclear Medicine 2009; 50(8): 1199 doi: 10.2967/jnumed.109.062117
|
| 52 |
Axel R. Pries, Annemiek J. M. Cornelissen, Anoek A. Sloot, Marlene Hinkeldey, Matthew R. Dreher, Michael Höpfner, Mark W. Dewhirst, Timothy W. Secomb, Jason A. Papin. Structural Adaptation and Heterogeneity of Normal and Tumor Microvascular Networks. PLoS Computational Biology 2009; 5(5): e1000394 doi: 10.1371/journal.pcbi.1000394
|
| 53 |
Jacek Wilczynski, Markus Duechler, Malgorzata Czyz. Targeting NF-κB and HIF-1 Pathways for the Treatment of Cancer: Part I. Archivum Immunologiae et Therapiae Experimentalis 2011; 59(4): 289 doi: 10.1007/s00005-011-0131-4
|
| 54 |
Clarinda W. L. Chua, Su Pin Choo. Targeted Therapy in Hepatocellular Carcinoma. International Journal of Hepatology 2011; 2011: 1 doi: 10.4061/2011/348297
|
| 55 |
Chaodong Li, Mei Ge, Yu Yin, Minyu Luo, Daijie Chen. Silencing expression of ribosomal protein L26 and L29 by RNA interfering inhibits proliferation of human pancreatic cancer PANC-1 cells. Molecular and Cellular Biochemistry 2012; 370(1-2): 127 doi: 10.1007/s11010-012-1404-x
|
| 56 |
Yoshiaki Mizuguchi, Toshihiro Takizawa, Eiji Uchida. Host cellular microRNA involvement in the control of hepatitis B virus gene expression and replication. World Journal of Hepatology 2015; 7(4): 696-702 doi: 10.4254/wjh.v7.i4.696
|
| 57 |
Ji-Hua Shi, Henrik S. Huitfeldt, Zhen-He Suo, Pål-Dag Line. Growth of hepatocellular carcinoma in the regenerating liver. Liver Transplantation 2011; 17(7): 866 doi: 10.1002/lt.22325
|
| 58 |
Yoshiaki Mizuguchi, Toshihiro Takizawa, Hiroshi Yoshida, Eiji Uchida. Dysregulated miRNA in progression of hepatocellular carcinoma: A systematic review. Hepatology Research 2016; 46(5): 391 doi: 10.1111/hepr.12606
|
| 59 |
Thomas Yau, Pierre Chan, Richard Epstein, Ronnie T Poon. Evolution of systemic therapy of advanced hepatocellular carcinoma. World Journal of Gastroenterology 2008; 14(42): 6437-6441 doi: 10.3748/wjg.14.6437
|
| 60 |
Wenjiao Zeng, Annette S.H. Gouw, Marius C. van den Heuvel, Peter J. Zwiers, Pieter E. Zondervan, Sibrand Poppema, Nong Zhang, Inge Platteel, Koert P. de Jong, Grietje Molema. The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization. Hepatology 2008; 48(5): 1517 doi: 10.1002/hep.22490
|
| 61 |
Federico Aucejo, Richard Kim, Nizar Zein, Cristiano Quintini, Teresa Diago Uso, Rocio Lopez, Bijan Eghtesad, John Fung, Charles Miller, Lisa Yerian. Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond milan criteria. Liver Transplantation 2009; 15(2): 169 doi: 10.1002/lt.21678
|
| 62 |
Maurizio Salvadori. Antineoplastic effects of mammalian target of rapamycine inhibitors. World Journal of Transplantation 2012; 2(5): 74-83 doi: 10.5500/wjt.v2.i5.74
|
| 63 |
Bernard E. Van Beers, Valérie Vilgrain. Biomarkers in abdominal imaging. Abdominal Imaging 2009; 34(6): 663 doi: 10.1007/s00261-008-9480-9
|
| 64 |
Rachel Friedman Ohana, Robin Hurst, Mike Rosenblatt, Sergiy Levin, Thomas Machleidt, Thomas A. Kirkland, Lance P. Encell, Matthew B. Robers, Keith V. Wood. Utilizing a Simple Method for Stoichiometric Protein Labeling to Quantify Antibody Blockade. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-43469-z
|
| 65 |
Zhiqin Zhu, Shulu Hu, Xingyi Zhong, Yangfeng Zhang, Xiuqiong Wu, Junhao Lin, Fengsheng Chen. EFNA5 suppresses cell proliferation and tumor metastasis in hepatoma via epithelial-to-mesenchymal transition. Discover Oncology 2024; 15(1) doi: 10.1007/s12672-024-01454-7
|
| 66 |
Hung Huynh. Molecularly targeted therapy in hepatocellular carcinoma. Biochemical Pharmacology 2010; 80(5): 550 doi: 10.1016/j.bcp.2010.03.034
|
| 67 |
Kai Zhu, Zhi Dai, Jian Zhou. Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomarker Research 2013; 1(1) doi: 10.1186/2050-7771-1-10
|
| 68 |
Laura Gramantieri, Francesca Fornari, Elisa Callegari, Silvia Sabbioni, Giovanni Lanza, Carlo M. Croce, Luigi Bolondi, Massimo Negrini. MicroRNA involvement in hepatocellular carcinoma. Journal of Cellular and Molecular Medicine 2008; 12(6a): 2189 doi: 10.1111/j.1582-4934.2008.00533.x
|
| 69 |
David Vauzour, Ana Rodriguez-Mateos, Giulia Corona, Maria Jose Oruna-Concha, Jeremy P. E. Spencer. Polyphenols and Human Health: Prevention of Disease and Mechanisms of Action. Nutrients 2010; 2(11): 1106 doi: 10.3390/nu2111106
|
| 70 |
Susan Kralian, Brian I. Carr. Hepatocellular Carcinoma. 2016; : 513 doi: 10.1007/978-3-319-34214-6_34
|
| 71 |
Makoto Meguro, Toru Mizuguchi, Masaki Kawamoto, Koichi Hirata. The Molecular Pathogenesis and Clinical Implications of Hepatocellular Carcinoma. International Journal of Hepatology 2011; 2011: 1 doi: 10.4061/2011/818672
|
| 72 |
Melanie B. Thomas, Deborah Jaffe, Michael M. Choti, Jacques Belghiti, Steven Curley, Yuman Fong, Gregory Gores, Robert Kerlan, Phillipe Merle, Bert O'Neil, Ronnie Poon, Lawrence Schwartz, Joel Tepper, Francis Yao, Daniel Haller, Margaret Mooney, Alan Venook. Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting. Journal of Clinical Oncology 2010; 28(25): 3994 doi: 10.1200/JCO.2010.28.7805
|
| 73 |
Lorenza Rimassa, Armando Santoro, Bruno Daniele, Domenico Germano, Antonio Gasbarrini, Stefania Salvagni, Gianluca Masi, Giovanni Abbadessa, Maria Lamar, Terri Goldberg, Camillo Porta. Tivantinib, a New Option for Second-line Treatment of Advanced Hepatocellular Carcinoma? The Experience of Italian Centers. Tumori Journal 2015; 101(2): 139 doi: 10.5301/tj.5000217
|
| 74 |
Shinji Tanaka, Shigeki Arii. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Science 2009; 100(1): 1 doi: 10.1111/j.1349-7006.2008.01006.x
|
| 75 |
E. A. Kotelnikova, M. D. Logacheva, E. R. Nabieva, M. A. Pyatnitskiy, D. V. Vinogradov, A. S. Makarova, A. V. Demin, A. G. Paleeva, O. S. Kremenetskaya, A. A. Penin, A. V. Klepikova, A. S. Kasianov, D. A. Shavochkina, N. E. Kudashkin, Yu. I. Patyutko, N. S. Mugue, A. S. Kondrashov, N. L Lazarevich. NGS-based identification of druggable alterations and signaling pathways – hepatocellular carcinoma case report. Biopolymers and Cell 2015; 31(6): 436 doi: 10.7124/bc.000901
|
| 76 |
Liliana Montella, Raffaele Addeo, Michele Caraglia, Salvatore Del Prete. Latest developments in targeted therapy for hepatocellular carcinoma. Expert Review of Anticancer Therapy 2010; 10(10): 1635 doi: 10.1586/era.10.146
|
| 77 |
D. Germano, V. Tinessa, E. Barletta, L. Cannella, B. Daniele. Targeted Therapy for Advanced Hepatocellular Cancer in the Elderly: Focus on Sorafenib. Drugs & Aging 2013; 30(11): 887 doi: 10.1007/s40266-013-0124-6
|
| 78 |
Jin Zhang, Xiangdong Jiang, Yingnan Jiang, Mingrui Guo, Shouyue Zhang, Jingjing Li, Jun He, Jie Liu, Jinhui Wang, Liang Ouyang. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs. European Journal of Medicinal Chemistry 2016; 108: 495 doi: 10.1016/j.ejmech.2015.12.016
|